Quipt Home Medical Corp.
NASDAQ•QIPT
CEO: Mr. Gregory J. Crawford
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-08-10
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
Contact Information
Market Cap
$109.70M
P/E (TTM)
-10.7
33
Dividend Yield
--
52W High
$3.27
52W Low
$1.35
52W Range
Rank54Top 66.0%
3.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$58.29M-8.88%
4-Quarter Trend
EPS
-$0.07+76.75%
4-Quarter Trend
FCF
$4.43M-54.10%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Months Revenue Decline Nine months revenue totaled $177.05M USD, down 4.1% due to external industry challenges impacting collections.
Operating Cash Flow Increase Operating cash flow provided $27.91M USD for nine months, showing a $2.51M USD increase year-over-year.
Stock Comp Expense Rises Stock-based compensation expense for nine months increased to $2.63M USD due to recent long-term incentives granted.
Post-Period Acquisition Closed Acquired Mediserve on July 1, 2025, for $2.60M USD cash/holdback, expanding footprint in Tennessee/Virginia.
Risk Factors
Net Loss Significantly Worsens Net loss for nine months reached $7.15M USD, worsening by $3.33M USD compared to prior year period.
Adjusted EBITDA Decreases Adjusted EBITDA declined $3.41M USD for nine months, settling at $41.02M USD due to operational pressures.
Regulatory and Activist Pressures DOJ CID investigation and activist shareholder actions introduce uncertainty and increase professional fees expense by $0.88M USD (9M).
Variable Rate Debt Exposure Variable rate debt exposes $7.01M USD principal to interest rate risk; 1% rise costs $70K annually in interest expense.
Outlook
Driving Organic Growth Focus Priorities include driving organic revenue growth, achieving operational net profit, and expanding Adjusted EBITDA moving forward.
Operational Efficiency Optimization Focus remains on optimizing structure, enhancing efficiencies, reducing redundancies, and centralizing processes for sustainable long-term growth.
Sufficient Liquidity Expected Current liquidity sources, including $14.30M USD credit availability, sufficient to fund operations for next twelve months.
Evaluating New Tax Legislation Evaluating impact of recently enacted OBBBA legislation regarding interest deductibility and capital expenditure expensing rules.
Peer Comparison
Revenue (TTM)
$1.21B
$229.68M
$133.08M
Gross Margin (Latest Quarter)
97.5%
81.6%
68.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PRE | $190.55M | -4.3 | -28.9% | 1.1% |
| APYX | $154.18M | -10.6 | -153.8% | 8.0% |
| ANIK | $139.02M | -4.2 | -22.1% | 12.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Dec 15, 2025
EPS:$0.03
|Revenue:$87.46M
Reports
All Years
Form 10-Q - Q3 2025
Period End: Jun 30, 2025|Filed: Aug 11, 2025|Revenue: $58.29M-8.9%|EPS: $-0.07+76.8%BeatForm 10-Q - Q2 2025
Period End: Mar 31, 2025|Filed: May 12, 2025|Revenue: $57.38M-6.3%|EPS: $-0.07+303.4%MissForm 10-Q - Q1 2025
Period End: Dec 31, 2024|Filed: Feb 10, 2025|Revenue: $61.38M-1.9%|EPS: $-0.03-30.6%BeatForm 10-K - FY 2024
Period End: Sep 30, 2024|Filed: Dec 16, 2024|Revenue: $245.92M+16.2%|EPS: $-0.16-128.6%MissForm 40-F/A - FY 2023
Period End: Sep 30, 2023|Filed: Apr 2, 2024|Revenue: $211.68M+51.3%|EPS: $-0.07-150.0%MissForm 40-F - FY 2023
Period End: Sep 30, 2023|Filed: Dec 22, 2023|Refer to amended dataForm 40-F - FY 2022
Period End: Sep 30, 2022|Filed: Dec 23, 2022|Revenue: $139.86M+36.6%|EPS: $0.14+170.0%BeatForm 40-F - FY 2021
Period End: Sep 30, 2021|Filed: Jan 27, 2022|Revenue: $102.35M+39.9%|EPS: $-0.20-17.6%Beat